Skip to main content

Table 2 Treatment regimen at conception

From: Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus

 

Zen/Doria remission

no remission

remission

p-value

n

37

59

 

GC (mg/day)

10.00 [8.00, 11.00]

4.00 [0.00, 5.00]

< 0.01

HCQ (%)

14 (37.8)

32 (54.2)

0.14

Tac (%)

13 (35.1)

13 (22.0)

0.24

CyA (%)

0 (0.0)

2 (3.4)

0.52

AZA (%)

2 (5.4)

4 (6.8)

1.0

MMF (%)

1 (2.7)

0 (0.0)

0.39

MZR (%)

0 (0.0)

1 (1.7)

1.0

MTX (%)

0 (0.0)

0 (0.0)

NA

BEL (%)

2 (5.4)

1 (1.7)

0.56

RTX/CY/PE/IVIg (%)

0 (0.0)

0 (0.0)

NA

aspirin (%)

12 (32.4)

30 (50.8)

0.093

  1. AZA, azathioprine; BEL, belimumab; CY, cyclophosphamide; CyA, cyclosporine; GC, glucocorticoid; HCQ, hydroxychloroquine; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MTX, methotrexate; MZR, MZR; NA, not available; PE, plasma exchange; PSL, prednisolone; RTX, rituximab; Tac, tacrolimus